PONS IP, a global consulting firm specialising in intellectual property, partners with joins AseBio, the leading association for the biotechnology sector in Spain. With this membership, the company reinforces its commitment to an ecosystem that consolidates its economic weight and international projection: according to data from the latest AseBio Report, the activity of biotechnology companies generated more than €13 billion in revenue (1.1% of GDP) and 131,214 jobs, with three times the productivity per employee and salaries that double the national average. In intellectual property, the sector registered 512 patent applications, of which 8 out of 10 applications were filed through the EPO/PCT system, and 121 biotech patent grants in 2024, underlining the global orientation of its members and the challenge of governing co-ownership in collaborations.
Nuria Marcos, General Manager of PONS IP, said in an interview given for AseBio that: “Intellectual property is not a formality. It is the lever that allows us to anticipate risks, prioritise resources and grow with greater security.” The board underlines that PONS IP’s contribution to AseBio will be based on two complementary pillars: intellectual property strategies aligned with the business and the work of its Technological Consulting Department, designed to accompany biotech companies in the decisions that define the success of a project.
Differential value at the service of the biotech company profile in Spain
The national biotechnology sector is largely made up of R&D-intensive SMEs that operate in consortia, seek competitive funding and compete in regulated markets. This is where PONS IP’s comprehensive approach offers clear synergies to AseBio members: the Technology Consulting Department integrates scientific, engineering, economic and legal profiles to cover the entire innovation cycle—from technological surveillance and freedom to operate (FTO) to technology valuation, competitive intelligence and advanced data management (including non-personal and synthetic data)—in addition to supporting European R&D consortia and projects. This model will enable members of Spain’s leading biotechnology association to align their intellectual property strategy with their business model, reduce the time‑to‑market and improve the regulatory quality of decisions, a critical point in advanced therapies, diagnostics and bioindustry.
At the same time, as the Technological Innovation Liaison Entity for the Community of Madrid, PONS IP will promote its commitment to training in IP culture and networking through AseBio as well as support for start-ups and SMEs through SCALE LAB, a project designed to promote technology transfer and international scaling through courses, conferences and specialised advice.
